Veru Inc. (VERU) P/E Ratio History
Deep ValueTrading at -2.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2021
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Veru Inc. (VERU) trades at a price-to-earnings ratio of -2.8x, with a stock price of $3.01 and trailing twelve-month earnings per share of $-0.65.
The current P/E is 100% below its 5-year average of 2777.8x. Over the past five years, VERU's P/E has ranged from a low of 83.7x to a high of 50882.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, VERU trades at a 112% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, VERU trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VERU DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VERU Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VERU P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 20.2Lowest | -Best | +1747%Best | |
| $7B | 66.5 | -Best | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VERU Historical P/E Data (2006–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | - | $85.30 | $1.02 | 83.7x | -97% |
| FY2021 Q1 | - | $86.50 | $0.00 | 50882.4x | +1429% |
| FY2016 Q4 | Sep 30 2016 | $12.20 | $0.01 | 1089.3x | -67% |
| FY2016 Q3 | - | $12.60 | $0.09 | 138.2x | -96% |
| FY2016 Q2 | - | $18.70 | $0.11 | 168.2x | -95% |
| FY2016 Q1 | - | $14.50 | $0.17 | 85.3x | -97% |
| FY2015 Q4 | Sep 30 2015 | $15.80 | $0.15 | 105.3x | -97% |
| FY2015 Q3 | - | $18.00 | $0.11 | 163.2x | -95% |
| FY2015 Q2 | - | $28.30 | $0.11 | 256.6x | -92% |
| FY2015 Q1 | Dec 31 2014 | $39.20 | $0.06 | 650.1x | -80% |
| FY2014 Q4 | - | $34.90 | $0.08 | 434.6x | -87% |
| FY2014 Q3 | Jun 30 2014 | $55.10 | $0.33 | 167.0x | -95% |
| FY2014 Q2 | Mar 31 2014 | $77.60 | $0.32 | 242.5x | -93% |
| FY2014 Q1 | - | $85.00 | $0.43 | 197.7x | -94% |
| FY2013 Q4 | Sep 30 2013 | $98.60 | $0.50 | 197.2x | -94% |
| FY2013 Q3 | Jun 30 2013 | $98.60 | $0.56 | 176.1x | -95% |
| FY2013 Q2 | Mar 31 2013 | $72.40 | $0.62 | 116.8x | -96% |
| FY2013 Q1 | Dec 31 2012 | $71.80 | $0.57 | 126.0x | -96% |
| FY2012 Q4 | Sep 30 2012 | $71.50 | $0.54 | 132.4x | -96% |
| FY2012 Q3 | Jun 30 2012 | $58.70 | $0.41 | 143.2x | -96% |
| FY2012 Q2 | Mar 31 2012 | $54.20 | $0.33 | 164.2x | -95% |
| FY2012 Q1 | Dec 31 2011 | $45.10 | $0.26 | 171.6x | -95% |
| FY2011 Q4 | Sep 30 2011 | $40.80 | $0.18 | 223.2x | -93% |
| FY2011 Q3 | - | $50.00 | $0.21 | 235.0x | -93% |
| FY2011 Q2 | - | $49.90 | $0.21 | 242.9x | -93% |
| FY2011 Q1 | Dec 31 2010 | $56.90 | $0.26 | 216.7x | -93% |
| FY2010 Q4 | - | $51.50 | $0.23 | 227.9x | -93% |
| FY2010 Q3 | Jun 30 2010 | $51.90 | $0.12 | 422.0x | -87% |
| FY2010 Q2 | Mar 31 2010 | $71.70 | $0.14 | 510.7x | -85% |
| FY2010 Q1 | - | $47.30 | $0.15 | 314.5x | -91% |
| FY2009 Q4 | Sep 30 2009 | $50.50 | $0.24 | 213.1x | -94% |
| FY2009 Q3 | - | $48.00 | $0.23 | 204.3x | -94% |
| FY2009 Q2 | - | $36.90 | $0.23 | 157.0x | -95% |
| FY2009 Q1 | Dec 31 2008 | $35.50 | $0.20 | 173.2x | -95% |
| FY2008 Q4 | - | $30.50 | $0.17 | 174.3x | -95% |
| FY2008 Q3 | Jun 30 2008 | $26.50 | $0.13 | 202.3x | -94% |
| FY2008 Q2 | Mar 31 2008 | $24.80 | $0.12 | 205.0x | -94% |
| FY2008 Q1 | Dec 31 2007 | $26.10 | $0.09 | 286.8x | -91% |
| FY2007 Q4 | Sep 30 2007 | $23.50 | $0.05 | 435.2x | -87% |
| FY2007 Q3 | Jun 30 2007 | $21.70 | $0.02 | 1315.2x | -60% |
| FY2007 Q2 | Mar 31 2007 | $22.30 | $0.01 | 3185.7x | -4% |
| FY2007 Q1 | Dec 31 2006 | $15.40 | $0.00 | 77000.0x | +2213% |
| FY2006 Q4 | Sep 30 2006 | $13.30 | $0.01 | 1156.5x | -65% |
| FY2006 Q3 | Jun 30 2006 | $13.50 | $0.00 | 3461.5x | +4% |
Average P/E for displayed period: 3328.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VERU — Frequently Asked Questions
Quick answers to the most common questions about buying VERU stock.
What is VERU's P/E ratio?
Veru Inc. (VERU) trailing twelve-month P/E ratio is -2.8x, based on TTM diluted EPS of $-0.65. The 5-year average P/E is 2777.8x and the historical range spans 83.7x to 50882.4x.
Is VERU stock overvalued or undervalued?
VERU trades at -2.8x P/E, below its 5-year average of 2777.8x. At the 0th percentile of its historical range (83.7x–50882.4x), the stock is priced at a discount to its own history.
Is VERU stock expensive?
No, VERU is not expensive on a historical basis. The current P/E of -2.8x is below the 5-year average of 2777.8x and sits at the 0th percentile of its valuation range.
What is VERU's historical P/E range?
Over the past 5 years, VERU's P/E ratio has ranged from 83.7x to 50882.4x, with a median of 168.2x and an average of 2777.8x. The current P/E of -2.8x places the stock at the 0th percentile of this range. Full historical data spans 2006–2021.
How does VERU's P/E compare to the S&P 500?
VERU trades at -2.8x P/E versus the S&P 500 median of 25.3x. The 111% discount to the market suggests lower growth expectations or perceived higher risk.
How does VERU's valuation compare to Healthcare peers?
Veru Inc. P/E of -2.8x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VERU's PEG ratio?
VERU PEG ratio is N/A, based on a P/E of -2.8x and EPS growth of 61.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VERU's earnings yield?
VERU earnings yield is N/A, the inverse of its -2.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.